MedTrace Logo

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

NCT01316185 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-08-08

No results posted yet for this study

Summary

The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.

Conditions

  • Hepatitis D

Interventions

DRUG

EBP921

Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.

Sponsors & Collaborators

  • Eiger BioPharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Brian Murphy, MD, MPH · Eiger BioPharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316185 on ClinicalTrials.gov